Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03132922 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MAGE-A4ᶜ¹º³²T for Multi-Tumor

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv30
  2. Lead sponsor: Adaptimmune to USWM CT, LLC Results first posted: May 7, 2026 · Primary endpoints: 4 to 3 · Secondary endpoints revised (7)v29 Show 3 more changesShow less
    • Results first posted: May 7, 2026
    • Primary endpoints: 4 to 3
    • Secondary endpoints revised (7)

    See this version in full on ClinicalTrials.gov ↗

  3. Enrollment target: estimated 52 to confirmed 71 Primary completion date changed from estimate of Sep 2032 to Dec 27, 2022 · Completion date: Sep 2035 to Sep 2032v28 Show 2 more changesShow less
    • Primary completion date changed from estimate of Sep 2032 to Dec 27, 2022
    • Completion date: Sep 2035 to Sep 2032
  4. Start date: Jul 5, 2017 to May 15, 2017 Eligibility criteria expanded, about 2 wordsv27 Show 1 more changeShow less
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial status: Recruiting to Active, Not Recruiting Site details revised at 11 of 11 sitesv26 Show 1 more changeShow less
    • Site details revised at 11 of 11 sites
Show 24 earlier versionsHide 24 earlier versions
  1. Site details revised at 6 of 11 sitesv25
  2. Start date: May 15, 2017 to Jul 5, 2017v24
  3. Site contacts updated at 1 of 11 sitesv23
  4. Site contacts updated at 1 of 11 sitesv22
  5. Primary completion date: Sep 2020 to Sep 2032 Study sites: 10 to 11v21 Show 1 more changeShow less
    • Study sites: 10 to 11
  6. Site details revised at 2 of 10 sitesv20
  7. Site details revised at 4 of 10 sitesv19
  8. Enrollment target: 42 to 52 Study sites: 9 to 10 · Interventions: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells (Genetic) to Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation (Radiation), Autologous genetically modified… · Study arms: 1 to 2 · 1 morev18 Show 4 more changesShow less
    • Study sites: 9 to 10
    • Interventions: Autologous genetically modified MAGE-A4ᶜ¹º³²T cells (Genetic) to Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation (Radiation), Autologous genetically modified…
    • Study arms: 1 to 2
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  9. Study sites: 8 to 9v17
  10. Study sites: 7 to 8v16
  11. Completion date: Sep 2020 to Sep 2035 Secondary endpoints: 6 to 7 · Site contacts updated at 2 of 7 sites · Eligibility criteria expanded, about 1 wordv15 Show 3 more changesShow less
    • Secondary endpoints: 6 to 7
    • Site contacts updated at 2 of 7 sites
    • Eligibility criteria expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  12. Site contacts updated at 1 of 7 sitesv14
  13. Study sites: 6 to 7v13
  14. Site details revised at 1 of 6 sitesv12
  15. Study sites: 5 to 6v11
  16. Enrollment target: 32 to 42 Study sites: 4 to 5 · Eligibility criteria shortened, about 1,212 words · Study description shortened, about 317 wordsv10 Show 3 more changesShow less
    • Study sites: 4 to 5
    • Eligibility criteria shortened, about 1,212 words
    • Study description shortened, about 317 words

    See this version in full on ClinicalTrials.gov ↗

  17. Study sites: 3 to 4v9
  18. Study sites: 2 to 3v8
  19. Site contacts updated at 1 of 2 sitesv7
  20. Re-verified, no change to tracked fieldsv6
  21. Eligibility criteria expanded, about 116 words Study description expanded, about 5 wordsv5 Show 1 more changeShow less
    • Study description expanded, about 5 words

    See this version in full on ClinicalTrials.gov ↗

  22. Study sites: 1 to 2v4
  23. Re-verified, no change to tracked fieldsv3
  24. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v2 Show 1 more changeShow less
    • Study sites: 0 to 1
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
USWM CT, LLC
8 trials monitored
See all monitored trials
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Non-Small Cell Lung Cancer (NSCLC)
2,932 trials monitored
See 157 trials at risk
Head & Neck Cancer
2,060 trials monitored
See 120 trials at risk
and 6 more diseases
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung, esophageal, gastric, synovial sarcoma, or myxoid/round call liposarcoma (MRCLS) tumor has the MAGE-A4 protein expressed. This study will take a subject's T cells and give them a T cell receptor protein that recognizes and attacks the tumors. This study has a substudy component that will investigate the safety and tolerability of MAGE-A4c1032T cell therapy in combination with low dose radiation in up to 10 subjects.
Trial Details
NCT Number NCT03132922
Lead Sponsor USWM CT, LLC
Conditions Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma +2 more
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov